LATE BREAKING ABSTRACT: Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination
H.T. Arkenu, M. Voskoboynik, J. Infante, A. Brenner, M. Patel, E. Borazanci, G. Falchook, L.R. Molife, S. Pant, Emma Dean, L. Pelosof, S. Jones, C. Rubino, W. McCulloch, V. Zhukova-Harrill, G. Kemble, M O'Farrell, H. Burris
Research output: Chapter in Book/Conference proceeding › Conference contribution › peer-review
Fingerprint
Dive into the research topics of 'LATE BREAKING ABSTRACT: Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination'. Together they form a unique fingerprint.